Telix Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 4:00 AM
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
13.05
Dividend yield
Beta
2.47
Market cap
$1.04B
Enterprise value
$1.02B
Company profile
| Primary activities | Development and commercialising molecularly targeted radiation products for the treatment of cancer. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | http://www.telixpharma.com |
| Mailing address | 55 Flemington Road Suite 401 North Melbourne VIC 3051 Australia |
| Phone / Fax | 61 3 3093 3897 / |
| Share registry | LINK MARKET SERVICES LIMITED |
Annual reports
| Published on | Report |
|---|---|
| 25 Feb 2021 | 2020 Annual Report |
Dividends
Telix Pharmaceuticals does not pay dividends.
Company Executives
As of May 2021, following are the company executives and directors listed on Telix Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Christian P. Behrenbruch Ph.D., BEng(Hons), MBA, DPhil(Oxon), J.D., GAICD | Co-Founder, MD, CEO & Exec. Director | 44 | 375.02k |
| Mr. Douglas Cubbin FCPA, GAICD | Group Chief Financial Officer | 332.32k | |
| Dr. Gabriel Liberatore B.Sc., M.A.I.C.D., M.B.A., Ph.D. | Group Chief Operating Officer | 341.15k | |
| Mr. Harry Marfatia | Director of Corp. Fin. | ||
| Dr. David N. Cade M.B.A., MBBS, M.D. | Chief Bus. Officer & Head of Investor Relations | ||
| Mr. Jonathan Barlow B.Sc., L.L.B. | Gen. Counsel | ||
| Ms. Amanda Griffin | Communications Mang. | ||
| Mr. Christian Davis | VP Sales and Marketing, EMEA | ||
| Ms. Margaret Haarhoff B.A. | Global Director of People & Culture | ||
| Dr. Shintaro Nishimura B.Sc., Ph.D. | Pres of Telix Japan |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-944.81%
Return on assets
-23.64%
Return on equity
-60.21%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Telix Pharmaceuticals is 1.04B and its enterprise value is 1.02B. The enterprise value to revenue ratio of TLX is 195.25.
The TLX's stocks Beta value is 2.47 making it 147% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Telix Pharmaceuticals (TLX)
Telix Pharmaceuticals (ASX:TLX) Frequently Asked Questions
1. What is Telix Pharmaceuticals's Stock Symbol?
Telix Pharmaceuticals trades on ASX under the ticker symbol "TLX".
2. What is Telix Pharmaceuticals's stock price today?
One share of TLX stock can currently be purchased for approximately $3.68.
3. How can I contact Telix Pharmaceuticals?
Telix Pharmaceuticals's mailing address is 55 Flemington Road Suite 401 North Melbourne VIC 3051 Australia. The company can be reached via phone at 61 3 3093 3897.
4. What is Telix Pharmaceuticals's official website?
The official website of Telix Pharmaceuticals is http://www.telixpharma.com.
5. Which share registry manages Telix Pharmaceuticals's stock?
Telix Pharmaceuticals's stock is managed by LINK MARKET SERVICES LIMITED.